Tag: Peijia

Peijia Medical (HKG:9996), a leading Chinese domestic player in the high-growth transcatheter valve therapeutic and neurointerventional procedural medical device markets, today announced financial results for the six months ended June 30, 2023 (“the period”). Financial Highlights During the period, the Company recorded an operating revenue of RMB224.9 million, representing an increase of 89.3% period-over-period. The increase in revenue was mainly attributable to: (i) The accelerated commercialization of transcatheter aortic valve replacement (“TAVR”) products (including the first-generation product TaurusOne and second-generation retrievable product TaurusElite) and expanded market share gains; (ii) The increased sales volume of existing neurointerventional products (including Tethys Intermediate ... Read more

Peijia Medical Limited (“Peijia Medical” or the “Company”, together with its subsidiaries, the “Group”, stock code: 9996), a leading domestic player in the high-growth transcatheter valve therapeutic and neurointerventional procedural medical device markets in China, announced its interim results for the six months ended June 30, 2022 (the “Period”).Performance Summary:— Revenue was RMB118.8 million, representing an increase of 129.8% from the same period of 2021.— Gross profit (excluding the amortization cost from purchase price allocation) was RMB87.6 million, representing an increase of 133.5% from the same period in 2021, and gross margin (excluding the amortization cost from purchase price allocation) ... Read more